SEC 13F Intelligence

Managers / Q4 2024 · view latest →

Lion Point Capital, LP

CIK 0001643354 · 375 PARK AVE, SUITE 2609, NEW YORK, NY, 10152 · 212-356-6200

Reported Value
$19M
Q4 2024
Positions
19
Filings on Record
31
2019–present window
Filed
Feb 14, 2025
original filing

Summary

Lion Point Capital, LP reported $19M in U.S.-listed holdings across 19 positions for Q4 2024.

Its largest position, IM8N, represents 13.3% of the portfolio.

Compared with Q3 2024, the fund opened 1 new position and exited 7.

Portfolio Metrics

Turnover
+6.1%
vs prior filed quarter
Top-10 Concentration
+74.8%
share of reported value
Largest Position
+13.3%
Insmed
New / Exited
1 / 7
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $636MQ4 ’18Q1 ’19: $1.1BQ2 ’19: $1.0BQ3 ’19: $897MQ4 ’19: $1.1BQ4 ’19Q1 ’20: $379MQ2 ’20: $412MQ3 ’20: $456MQ4 ’20: $519MQ4 ’20Q1 ’21: $550MQ2 ’21: $579MQ3 ’21: $533MQ4 ’21: $373MQ4 ’21Q1 ’22: $431MQ2 ’22: $878MQ3 ’22: $454MQ4 ’22: $703MQ4 ’22Q1 ’23: $243MQ2 ’23: $221MQ3 ’23: $224MQ4 ’23: $200MQ4 ’23Q1 ’24: $179MQ2 ’24: $55MQ3 ’24: $45MQ4 ’24: $19MQ4 ’24Q1 ’25: $16MQ2 ’25: $15MQ3 ’25: $18MQ4 ’25: $19MQ4 ’25Q1 ’26: $17Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 87.1%Other: 12.9%
  • Common Stock · 87.1% · $17M
  • Other · 12.9% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BLUEBIRD BIO INCNEW+78.9K78.9K+$658,126$658,126
ISHARES TRSOLD OUT−82.5K0−$18M$0
MIRMMIRUM PHARMACEUTICALS INCSOLD OUT−45.0K0−$2M$0
MARINUS PHARMACEUTICALS INCSOLD OUT−693.8K0−$1M$0
BLUEBIRD BIO INCSOLD OUT−1.58M0−$819,904$0
LUMOS PHARMA INCSOLD OUT−39.6K0−$153,209$0
MSFTMICROSOFT CORPSOLD OUT−1000−$43,030$0
GOOGALPHABET INCSOLD OUT−1000−$16,719$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2024

19 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1IM8NINSMED INChistory →COM PAR $.0113.27%$3M36.7K
2MISTMILESTONE PHARMACEUTICALS INhistory →COM12.68%$2M1.03M
3GONGERON CORPhistory →COM9.27%$2M500.0K
4ARDXARDELYX INChistory →COM8.90%$2M335.4K
5FRXFENNEC PHARMACEUTICALS INChistory →COM6.48%$1M195.7K
6BBIOBRIDGEBIO PHARMA INChistory →COM5.79%$1M40.3K
7MLYSMINERALYS THERAPEUTICS INChistory →COM5.09%$972,49079.0K
8KINIKSA PHARMACEUTICALS LTDORD SHS CL A4.75%$907,90245.9K
9BIOHAVEN LTDCOM4.44%$847,84522.7K
10BNTCBENITEC BIOPHARMA INChistory →COM NEW4.10%$783,06062.0K
11SNDXSYNDAX PHARMACEUTICALS INChistory →COM3.81%$727,10055.0K
12JSPRJASPER THERAPEUTICS INChistory →COM NEW3.58%$684,16032.0K
13AVADEL PHARMACEUTICALS PLCCOM SHS3.52%$672,64064.0K
14IRONDISC MEDICINE INChistory →COM3.52%$672,04010.6K
15BLUEBIRD BIO INCCOM NEW3.45%$658,12678.9K
16ARQTARCUTIS BIOTHERAPEUTICS INChistory →COM3.38%$644,95946.3K
17RGNXREGENXBIO INChistory →COM2.34%$446,40857.8K
18MCRB1EURSERES THERAPEUTICS INChistory →COM1.48%$283,172340.8K
19SPRUCE BIOSCIENCES INCCOM0.16%$31,50075.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$17M35May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$19M39Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$18M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$15M19Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$16M21May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$19M19Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$45M25Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$55M27Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$179M32May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$200M30Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$224M31Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$221M30Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$243M31May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$703M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$454M41Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$878M40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$431M35May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$373M33Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$533M38Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$579M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$550M30May 19, 2021RESTATEMENTchanges · EDGAR ↗
Q4 2020$519M24Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$456M24Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$412M24Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$379M25May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.1B26Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$897M26Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.0B24Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.1B24May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$636M35Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.